via Mayo Clinic
Scientific investigations sometimes result in serendipitous discoveries which shift the investigations from one focus to another. In the case of researchers at Mayo Clinic in Arizona, studies addressing obesity’s impact on cancer treatment resulted in an unexpected discovery that shifted the focus from cancer to obesity. The investigators observed that two common cancer-fighting drugs sparked significant weight loss in the obese mice, even though the mice continued their excessive consumption of a high-fat diet.
These results, which are part of a Mayo Clinic study, were reported in the Jan. 17 edition of Oncotarget.
“We were surprised to observe that when morbidly obese mice were treated with certain cancer-fighting drugs, the drugs not only targeted their cancers, but also tended to spontaneously resolve their obesity ? even with undiminished gorging on a high-fat diet,” says Mayo Clinic cancer immunotherapist Peter Cohen, M.D., who co-led the study with postdoctoral fellow Cheryl Myers, Ph.D. and Mayo Clinic immunologist Sandra Gendler, Ph.D.
“Importantly, two chemotherapy agents ? methotrexate and cyclophosphamide ? could be dosed to completely reverse obesity without detectable toxicity, even in mice without cancer,” explains Dr. Myers. “Interestingly, these drugs are already used to treat some noncancerous conditions, such as rheumatoid arthritis.”
More research needs to be done to see if the same outcome can be achieved in morbidly obese patients.
“The ease with which this weight loss was achieved in mice ? even with continued caloric binging ? is in stark contrast to the Herculean difficulties morbidly obese patients experience trying to preserve weight loss through dietary restraint,” adds Dr. Gendler.
The weight reduction observed in the obese mice was not attributable to trivial explanations, such as a decrease in dietary intake, increased energy expenditure or malabsorption. Instead, the investigators identified multiple effects of methotrexate or cyclophosphamide that worked together to expedite loss of excessive weight in mice. Much like chemotherapy’s well-known ability to decrease red and white blood cell precursors transiently, methotrexate or cyclophosphamide depleted fat cell precursors, leading to much decreased fat storage. “This meant that excessive dietary calories had to go somewhere else in the body instead, such as to the liver,” explains Dr. Cohen.
“Surprisingly, the liver maintained a robust level of metabolic activity during methotrexate or cyclophosphamide treatment, but was nearly shut down in regards to fat production and fat storage,” adds Dr. Myers.
“Based on our composite data,” explains Dr. Gendler, “it appears that methotrexate or cyclophosphamide can induce the livers of obese mice to burn off rather than accumulate excessive dietary fat. This results in desirable weight reduction instead of increased obesity, even with continued caloric binging.”
The study sets the stage for further research, exploring how these metabolic mechanisms could reduce the need for severe dietary constraints in morbidly obese individuals.
Learn more: Mayo Clinic researchers identify cancer-fighting drugs that help morbidly obese mice to lose weight
The Latest on: Methotrexate and cyclophosphamide
Expert Discusses Strategies for Advancing Pediatric ALL Care - OncLive
September 20, 2017 - At the 2017 Society of Hematology Oncology Annual Meeting, pediatric hematologist Ching-Hon Pui, MD, said the effort to improve outcomes in pediatric acute lymphoblastic leukemia (ALL) should follow insight provided by next-generation sequencing (NGS) ...
Challenges, Needs to Improve Treatment of Pediatric ALL - Targeted Oncology
September 15, 2017 - Effective postremission therapy may still cure certain patients without transplant, such as high-dose methotrexate for hyperdiploid >50 ALL and the combination of cyclophosphamide, cytarabine (Depocyt), and mercaptopurine for early T-cell precursor ALL.
Systemic Lupus Erythematous SLE Drugs Market Assessment and Forecast Report by Future Market Insights - satPRnews (press release)
September 8, 2017 - BLyS-specific Inhibitors or Monoclonal Antibodies (MAbS): Belimumab (Benlysta), Immunosuppressive Agents/Immune Modulators, Azathioprine (Imuran), Methotrexate (Rheumatrex), Cyclophosphamide (Cytoxan), Anticoagulants, Low-dose aspirin, Heparin ...
Pediatric Brain Tumor Market is Expected to grow at a CAGR of 4.1% by 2023 - Medgadget (blog)
September 4, 2017 - Chemotherapy includes carboplatin, carmustine (BCNU), cisplatin, cyclophosphamide, etoposide, lomustine (CCNU), methotrexate, temozolomide, thiotepa, vincristine, and others. Drug treatment is further sub-segmented into corticosteroids, anti-seizure ...
Adjuvant Capecitabine for Breast Cancer Can Replace CMF After Epirubicin - Cancer Network
June 28, 2017 - Studies have shown, though, that epirubicin followed by cyclophosphamide, methotrexate, and fluorouracil (CMF) carries significant toxicity. The phase III TACT2 trial used a 2 × 2 factorial design to test whether accelerating the epirubicin portion of ...
Biotherapy and chemotherapy: Oral complications - Dentistry IQ
June 20, 2017 - The increased survival rate of autoimmune and cancer patients was attributed to chemotherapy agents such as methotrexate and cyclophosphamide, and biotherapy agents such as rituximab, infliximab, and belimumab. In addition to the benefits these agents ...
CellCept, Cytoxan Can Significantly Reduce Skin Thickening in Systemic Sclerosis, Study Shows - Scleroderma News
June 1, 2017 - Several immune-modulatory drugs such as Trexall (methotrexate) and Cytoxan have been studied as treatment for skin thickening and interstitial lung disease in SSc. However, until now, no one had performed an in-depth, long-term analysis of the effect ...
Vasculitis: 5 Drugs to Control This Mysterious Blood Vessel Illness - Health Essentials from Cleveland Clinic (blog)
April 3, 2017 - Cyclophosphamide is a tried-and-true older drug, taken orally or intravenously, that doctors also use to treat cancer. It is currently ... Methotrexate can be associated with lowering of the blood counts, irritation of the lungs (called pneumonitis ...
Immunosuppressants Only of 'Weak' Benefit to Diffuse Scleroderma Patients, Study Reports - Scleroderma News
February 16, 2017 - Physicians could choose to treat patients with one of four approaches: methotrexate, CellCept (mycophenolate mofetil), Cytoxan (cyclophosphamide), or no immunosuppressant. Patients were assessed every third month, with a final examination after two ...
Researchers find cancer-fighting drugs help morbidly obese mice lose weight - Science Daily
January 18, 2017 - "Importantly, two chemotherapy agents -- methotrexate and cyclophosphamide -- could be dosed to completely reverse obesity without detectable toxicity, even in mice without cancer," explains Dr. Myers. "Interestingly, these drugs are already used to ...